\_\_\_\_\_\_

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2008; month=12; day=18; hr=9; min=29; sec=50; ms=740; ]

\_\_\_\_\_\_

## Validated By CRFValidator v 1.0.3

Application No: 10521038 Version No: 2.0

Input Set:

Output Set:

**Started:** 2008-12-03 17:18:09.746 **Finished:** 2008-12-03 17:18:10.443

**Elapsed:** 0 hr(s) 0 min(s) 0 sec(s) 697 ms

Total Warnings: 11
Total Errors: 0

No. of SeqIDs Defined: 11

Actual SeqID Count: 11

Error code		Error Description				
W	213	Artificial or	Unknown	found i	n <213>	in SEQ ID (1)
W	213	Artificial or	Unknown	found i	n <213>	in SEQ ID (2)
W	213	Artificial or	Unknown	found i	n <213>	in SEQ ID (3)
W	213	Artificial or	Unknown	found i	n <213>	in SEQ ID (4)
W	213	Artificial or	Unknown	found i	n <213>	in SEQ ID (5)
W	213	Artificial or	Unknown	found i	n <213>	in SEQ ID (6)
W	213	Artificial or	Unknown	found i	n <213>	in SEQ ID (7)
W	213	Artificial or	Unknown	found i	n <213>	in SEQ ID (8)
W	213	Artificial or	Unknown	found i	n <213>	in SEQ ID (9)
W	213	Artificial or	Unknown	found i	n <213>	in SEQ ID (10)
W	213	Artificial or	Unknown	found i	n <213>	in SEQ ID (11)

## SEQUENCE LISTING

```
<110> Wieslab AB
     Roos, Johanna
      Daha, Mohamed R.
      Bouwman, Lee
      Hack, Cornelis Erik
<120> LECTIN PATHWAY DEFICIENCY ASSAY
<130> 05822.0319USWO
<140> 10521038
<141> 2008-12-03
<150> PCT/SE2003/001211
<151> 2003-07-11
<150> SW0202325-7
<151> 2002-07-26
<150> SW0202880-1
<151> 2002-09-30
<160> 11
<170> PatentIn version 3.5
<210> 1
<211> 18
<212> PRT
<213> Artificial
<220>
<223> synthetic peptide
<400> 1
Thr Asp Gly Asp Lys Ala Phe Val Asp Phe Leu Ser Asp Glu Ile Lys
    5
                  10
Glu Glu
<210> 2
<211> 8
<212> PRT
<213> Artificial
<220>
<223> synthetic peptide
```

<400> 2

```
<210> 3
<211> 7
<212> PRT
<213> Artificial
<220>
<223> synthetic peptide
<400> 3
Ala Glu Ala Lys Ala Lys Ala
             5
<210> 4
<211> 11
<212> PRT
<213> Artificial
<220>
<223> synthetic peptide
<400> 4
Val Gln Val His Asn Ala Lys Thr Lys Pro Arg
<210> 5
<211> 15
<212> PRT
<213> Artificial
<220>
<223> synthetic peptide
<400> 5
Cys Glu Gly Pro Phe Gly Pro Arg His Asp Leu Thr Phe Cys Trp
              5
                              10
                                                    15
<210> 6
<211> 14
<212> PRT
<213> Artificial
<220>
<223> synthetic peptide
<400> 6
```

Leu Glu Gln Gly Glu Asn Val Phe Leu Gln Ala Thr Leu Leu

Lys Asp Ile Arg Cys Lys Asp Asp

```
1 5 10
```

```
<210> 7
<211> 12
<212> PRT
<213> Artificial
<220>
<223> synthetic peptide
<400> 7
Cys Arg Trp Asp Gly Ser Trp Gly Glu Val Arg Cys
<210> 8
<211> 12
<212> PRT
<213> Artificial
<220>
<223> synthetic peptide
<400> 8
Cys Met Trp Val Arg Met Trp Gly Asp Val Asn Cys
<210> 9
<211> 12
<212> PRT
<213> Artificial
<220>
<223> synthetic peptide
<400> 9
Cys Phe Trp Ala Gly Lys Phe Gly Leu Gly Thr Cys
<210> 10
<211> 12
<212> PRT
<213> Artificial
<220>
<223> synthetic peptide
<400> 10
Cys Lys Asp Arg Trp Val Val Glu Glu Arg Cys Cys
```

5

```
<210> 11
<211> 11
<212> PRT
<213> Artificial
<220>
<223> synthetic peptide
<400> 11

Cys Trp Asn Arg Phe Lys Lys Met Asp Arg Cys
```